XPO1 Inhibitor (ATG-010) Plus Chemotherapy per Investigator's Choice for Heavily Pretreated Patients with Relapsed or Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL) and Extranodal NK/T-Cell Lymphoma (ENKTL):: Preliminary Results from a Multicenter, Single-Arm, Phase Ib Study (TOUCH Trial)

被引：3
|
作者：
Huang, Huiqiang [1 ]
Gao, Yan [1 ]
Zhang, Huilai [2 ]
Zhou, Keshu [3 ]
Wu, Jianqiu [4 ]
Cai, Zhen [5 ]
Jing, Hongmei [6 ]
Fan, Lei [7 ]
Lou, Sai [8 ]
Fei, Yizhou [8 ]
Wang, Aihua [8 ]
Lynch, Kevin [8 ]
机构：
[1] Sun Yat Sen Univ Canc Ctr, Dept Med Oncol, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou, Peoples R China
[2] Tianjin Med Univ Canc Inst & Hosp, Dept Lymphoma, Natl Clin Res Ctr Canc, Tianjins Clin Res Ctr Canc, Tianjin, Peoples R China
[3] Zhengzhou Univ, Henan Canc Hosp, Dept Hematol, Affiliated Canc Hosp, Zhengzhou, Peoples R China
[4] Nanjing Med Univ, Jiangsu Inst Canc Res, Dept Med Oncol, Affiliated Canc Hosp, Nanjing, Peoples R China
[5] Zhejiang Univ, Affiliated Hosp 1, Dept Hematol, Bone Marrow Transplantat Ctr,Coll Med, Hangzhou, Zhejiang, Peoples R China
[6] Peking Univ Third Hosp, Dept Hematol & Lymphoma Res Ctr, Beijing, Peoples R China
[7] Nanjing Med Univ, Jiangsu Prov Hosp, Dept Hematol, Collaborat Innovat Ctr Canc Personalized Med,Firs, Nanjing, Peoples R China
[8] Antengene Therapeut Ltd, Shanghai, Peoples R China
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-147100
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2452
引用
收藏
页数：4
相关论文
共 30 条
  • [1] XPO1 Inhibitor (ATG-010) Plus GemOx Regimen for Heavily Pretreated Patients with Relapsed or Refractory (R/R) T and NK-Cell Lymphoma:Updates of the Phase Ib Touch Study
    Huang, Huiqiang
    Gao, Yan
    Zhang, Huilai
    Zhou, Keshu
    Wu, Jianqiu
    Cai, Zhen
    Jing, Hongmei
    Fan, Lei
    Lou, Sai
    Fei, Yizhou
    Wang, Aihua
    Lynch, Kevin
    BLOOD, 2022, 140 : 6554 - 6555
  • [2] Sintilimab for relapsed/refractory (r/r) extranodal NK/T-cell lymphoma (ENKTL): A multicenter, single-arm, phase 2 trial (ORIENT-4).
    Tao, Rong
    Fan, Lei
    Song, Yongping
    Hu, Yu
    Zhang, Wei
    Wang, Yafei
    Xu, Linxinyu
    Zhou, Hui
    Li, Jianyong
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [3] Selinexor combined with tislelizumab in patients with relapsed or refractory extranodal NK/T-cell lymphoma (R/R ENKTL): Results of dose escalation of cohort C, from a multicenter, single-arm, phase I/II study (TOUCH)
    Liu, Chuanxu
    Gao, Yan
    Yu, Yang
    Guo, Zhi
    Zhao, Jun
    Tao, Rong
    Huang, Huiqiang
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [4] Phase 2 Search Study:XPO1 Inhibitor (ATG-010) Monotherapy in Heavily Pretreated Chinese Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Song, Yuqin
    Cai, Qingqing
    Zhang, Qingyuan
    Sun, Xiuhua
    Yang, Haiyan
    Yao, Zhihua
    Zou, Liqun
    Zhang, Liling
    Cao, Junning
    Wang, Tingyu
    Li, Lanfang
    Liu, Yao
    Jing, Hongmei
    Gao, Sujun
    Ding, Kaiyang
    Liu, Bingshan
    Zhao, Jun
    Zhu, Jun
    BLOOD, 2023, 142
  • [5] Sintilimab for Relapsed/Refractory Extranodal NK/T-Cell Lymphoma: A Multicenter, Single-Arm, Phase 2 Trial (ORIENT-4)
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (08) : 13 - 14
  • [6] Safety and Efficacy of Mitoxantrone Hydrochloride Liposome in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma and Extranodal NK/T-Cell Lymphoma: A Multicenter, Single-Arm, Open-Label, Phase 2 Clinical Trial
    Huang, Hui-qiang
    Huang, Yunhong
    Yan, Gao
    Yang, Haiyan
    Zhang, Qingyuan
    Yang, Runxiang
    Zhou, Min
    Li, Yufu
    Li, Yan
    Liu, Lihong
    Zhou, Hui
    Jing, Hongmei
    Peng, Zhigang
    Yu, Ding
    Zhang, Rong Yan
    Xu, Bing
    Zhang, Xiaohong
    Qi, Junyuan
    Ma, Liping
    Chen, Shan
    Xue, Jianfei
    BLOOD, 2019, 134
  • [7] Sintilimab for relapsed/refractory (r/r) extranodal NK/T cell lymphoma (ENKTL): Extended follow-up on the multicenter, single-arm phase II trail (ORIENT-4).
    Li, Jianyong
    Tao, Rong
    Fan, Lei
    Song, Yongping
    Hu, Yu
    Zhang, Wei
    Wang, Yafei
    Xu, Linxinyu
    Sun, Xing
    Zhou, Hui
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [8] A multicenter, open-label, single-arm, phase Ib clinical trial of HH2853 treatment in patients with relapsed and/or refractory peripheral T-cell lymphoma
    Huangming Hong
    Zegeng Chen
    Mingzhi Zhang
    Zhigang Peng
    Jianzhen Shen
    Yuerong Shuang
    Hui Zhou
    Hongqiang Guo
    He Huang
    Fei Li
    Zhengzi Qian
    Lihong Liu
    Liang Wang
    Wei Yang
    Liling Zhang
    Pengcheng He
    Shen Qian
    Fugen Li
    Meng Li
    Tongyu Lin
    Journal of Hematology & Oncology, 18 (1)
  • [9] A Multicenter, Open-Label, Single-Arm, Phase Ib Clinical Trial of HH2853 in the Treatment of Patients with Relapsed and/or Refractory Peripheral T-Cell Lymphoma
    Hong, Huangming
    Zhang, Mingzhi
    Peng, Zhigang
    Shen, Jianzhen
    Shuang, Yuerong
    Zhou, Hui
    Guo, Hongqiang
    Huang, He
    Li, Fei
    Qian, Zhengzi
    Liu, Lihong
    Wang, Liang
    Yang, Wei
    Zhang, Liling
    He, Pengcheng
    Qian, Shen
    Li, Fugen
    Li, Meng
    Lin, Tongyu
    BLOOD, 2023, 142
  • [10] Anti-PD-1 Antibody (Sintilimab) Plus Histone Deacetylase Inhibitor (Chidamide) for the Treatment of Refractory or Relapsed Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (r/r-ENKTL): Preliminary Results from a Prospective, Multicenter, Single-Arm, Phase Ib/II Trial (SCENT)
    Gao, Yan
    Huang, Huiqiang
    Wang, Xiaoxiao
    Bai, Bing
    Zhang, Liling
    Xiao, Yin
    Liu, Xinxiu
    Li, Wenyu
    Xu, Wei
    Feng, Ru
    Chen, Yu
    Wu, Huijing
    Li, Jibin
    Wu, Xue
    BLOOD, 2020, 136
123